Orphan diseases are perhaps the most cruel of illnesses. Frequently life threatening, they afflict only a very small percentage of the world’s populations, thereby discouraging research and making any drugs that are developed prohibitively expensive. Are pharmaceutical companies that do develop treatments merely getting fair return on their investment, or
Continue reading